Become a Creator today!Start creating today - Share your story with the world!
Start for free
00:00:00
00:00:01
Capillary Refill Time (CRT)
1 Plays4 months ago
In this episode, Dr. Sergio Zanotti discusses the assessment of peripheral perfusion as a tool to guide treatment in septic shock. Specifically, he dives into Capillary Refill Time. He is joined by Dr. Eduardo Kattan, a critical care and anesthesia physician. Dr. Kattan is an Assistant Professor at the Pontificia Catholic University of Chile, where he also serves as Adult Critical Care Program Director and Director of Research and Academics in the Department of Critical Care Medicine. A prolific investigator, he focuses his research on septic shock and medical education. Dr. Rattan is the Co-Principal Investigator of the recently published ANDROMEDA-SHOCK 2 clinical trial.
Additional resources:
Personalized Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock. The ANDORMEDA-SHOCK-2 Randomized Clinical Trial. JAMA 2025: https://jamanetwork.com/journals/jama/fullarticle/2840823
Effect of Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on. 28-Day Mortality Among Patients With Septic Shock. The ANDROMEDA-SHOCK Randomized Clinical Trial. JAMA 2019: https://jamanetwork.com/journals/jama/fullarticle/2724361
Perspectives on peripheral perfusion assessment. Eduardo Kattan, et al. Curr Opin Crit Care 2023: https://pubmed.ncbi.nlm.nih.gov/37078639/
Books mentioned in this episode:
The Little Prince. By Antoine de Saint-Exupery: https://bit.ly/49YcSRJ
The Autumn Ghost: How the Battle Against a Polio Epidemic Revolutionized Modern Medical Care. By Hannah Wunsch: https://bit.ly/4i9PiUf
Recommended
Transcript
Introduction to Critical Matters
00:00:06
Speaker
Welcome to Critical Matters, a sound podcast covering a broad range of topics related to the practice of intensive care medicine.
00:00:14
Speaker
Sound provides comprehensive critical care programs to hospitals across the country.
00:00:19
Speaker
To learn more about our programs and career opportunities, visit www.soundphysicians.com.
00:00:26
Speaker
And now your host, Dr. Sergio Zanotti.
Focus on Septic Shock and Peripheral Perfusion
00:00:31
Speaker
Septic shock causes a wide range of pathophysiological changes in critically ill patients.
00:00:37
Speaker
Hemodynamic resuscitation is a key component of therapy for patients with septic shock.
00:00:42
Speaker
Research in septic shock has focused on identifying the best resuscitation strategy to improve patient outcomes.
00:00:48
Speaker
In today's episode of the podcast, we will discuss the assessment of peripheral perfusion as a tool to guide treatment in septic shock.
Guest Introduction: Dr. Catan's Insights
00:00:55
Speaker
Specifically, we will discuss capillary refilled time.
00:00:58
Speaker
Our guest is Dr. Eduardo Catan, a critical care and anesthesia physician.
00:01:02
Speaker
Dr. Catan is an assistant professor at the Pontificia Catholic University of Chile, where he also serves as adult critical care program director and director of research and academics in the Department of Critical Care Medicine.
00:01:15
Speaker
A prolific investigator, he focuses his research on septic shock in medical education.
00:01:19
Speaker
Dr. Rattan is a co-principal investigator of the recently published Andromeda Shock 2 clinical trial.
00:01:27
Speaker
Eduardo, welcome to Critical Matters.
00:01:30
Speaker
Thank you, Sergio.
00:01:30
Speaker
It's such an honor to be here.
00:01:32
Speaker
And I'm eager to spend this time talking about research, life, and our study.
00:01:38
Speaker
Awesome, man.
00:01:38
Speaker
Really a privilege to have you on.
00:01:40
Speaker
And I would like to start with the first question is, why do you think intensivists should care about this topic?
Challenges in Tissue Perfusion Assessment
00:01:48
Speaker
So I think that, like...
00:01:51
Speaker
behind when we're facing a patient with septic shock or shock, what we're trying to do is, let's say, try to manipulate macromodynamics to finally improve tissue perfusion.
00:02:02
Speaker
The issue is, the main issue is that assessing tissue perfusion is an imperfect, let's say,
00:02:08
Speaker
area, we do not have, let's say, beyond research practice where we can see the microcirculation with these handheld microscopes, we have surrogates to assess tissue perfusion or the adequacy of tissue perfusion, which can be a two-edged sword because it can tell us when not only to keep doing resuscitation, giving fluids, vasopressor, rhinocopes, and on the other hand, when to stop and avoid the atrogenic harm.
00:02:36
Speaker
One of the windows that Professor Max Harry Weil already 30 years ago had shown or exposed was to assess the skin as one of the territories that could tell us about the adequacy of tissue perfusion of other organs that are quite more important as the liver, the intestines, etc.
00:02:57
Speaker
So it's one of our key windows in which we can assess the perfusion and the adequacy of flow with other organs.
00:03:06
Speaker
And as we talk about flow, especially in septic shock, which is obviously the focus of the Andromeda shock trial, could you give us an overview of the basics of pathophysiology in terms of shunting and why assessing the peripheral tissue might be of value?
Pathophysiological Changes in Septic Shock
00:03:24
Speaker
Of course.
00:03:25
Speaker
So even though we usually learn, let's say, in medical school that septic shock is a, let's say, high-cardic output vasoplegic shock, there is more beyond that, and there are a few researchers in the last few years that show quite heterogenic patterns on the macromodynamic side.
00:03:43
Speaker
Let's say there are patients that go with, let's say, persistent hypovolemia, other that have left or right ventricular dysfunction, and other, like,
00:03:54
Speaker
the usual clinical hyperkinetic septic shock.
00:03:58
Speaker
However, these macro-hemodynamic patterns is not the only thing that's, let's say,
00:04:03
Speaker
determining an inability to deliver oxygen to the tissues.
00:04:07
Speaker
There's also microcirculatory derangements, and there's heterogeneity of flow, microtrombosis of the microcirculation, there's a component of venous congestion in some cases.
00:04:18
Speaker
So there's two pathophysiological processes that are intertwined, are coexisting in this, let's say, in this difficult phases of septic shock, in which we do not have only to resuscitate the macro, but
00:04:33
Speaker
consider its coupling and the hemodynamic coherence with the micro-stimulation.
00:04:38
Speaker
In terms of assessing the peripheral perfusion, I had many years ago been part of some studies that were looking at sublingual capillary microflow.
00:04:46
Speaker
That didn't really translate useful tools at the bedside, but I understand that a lot of your research has been focused on trying to find tools that actually bedside clinicians can utilize.
Assessing Peripheral Perfusion: Tools and Techniques
00:04:58
Speaker
What are some of the tools that are available for evaluation of peripheral perfusion today?
00:05:04
Speaker
So the skin is one of the largest organs, let's say, and there are many tools that can help us assess the peripheral perfusion.
00:05:14
Speaker
Some are technological, for example, you can use temperature gradients from the periphery to the central temperature with skin thermistors, like the peripheral perfusion index that's derived from the platysmography.
00:05:27
Speaker
It's also another tool that's been consistently used in critical care and anesthesia.
00:05:33
Speaker
There are some other techniques such as the laser Doppler, which measures the skin blood flow with a small non-invasive sensor that you can place it anywhere in the skin.
00:05:45
Speaker
and there are non-technological, let's say, clearly clinical methods like the mottling score which uses this semi-quantitative ordinal scale to address the extension of the mottling from the kneecaps to the groin or capillary ratio time that
00:06:04
Speaker
when it's done, let's say, in a standardized or semi-standardized way, can help us not only identify a problem, but also to quantify it as well with degrees of severity.
00:06:18
Speaker
We'll dive into more details with the capillary refill time, Eduardo, in a second.
00:06:23
Speaker
But in terms of the modeling score and some of the other devices that you have mentioned, my understanding is that mostly the literature suggests that they are very good prognostic factors.
00:06:34
Speaker
Is that correct?
00:06:35
Speaker
Yes.
00:06:36
Speaker
Yes, yes, I think especially for the modeling score, there's a big bunch of evidence and even meta-analysis led by Professor Hafidah Tufela in Paris, where the modeling score, let's say, the persistence of an abnormal modeling score during early resuscitation has been consistently associated with worse outcomes.
00:07:01
Speaker
It has a prognostic value, especially 14 or 28-day mortality.
00:07:05
Speaker
So when you see an abnormal Motley score, it's a linear relationship with mortality.
00:07:12
Speaker
Before we move on to capital refilled time, could you just give our audience a brief description of what the Motley score is?
00:07:19
Speaker
Of course, of course, of course.
00:07:21
Speaker
So the mottling score, let's say, you can, it's a visual scale in which goes from one to five, and it covers the extent of, let's say, this mottled skin on the kneecap.
00:07:36
Speaker
So one is just a small area over the kneecap.
00:07:39
Speaker
Number two goes the full area of the kneecap.
00:07:43
Speaker
Score number three goes halfway through the femur, let's say.
00:07:48
Speaker
Number four almost reaches the inguinal ligament.
00:07:54
Speaker
And over the inguinal ligament goes the most severe one.
00:07:58
Speaker
That's number five.
00:07:59
Speaker
So it's a visual scale that you can apply at the bedside at no cost.
00:08:03
Speaker
And you can...
00:08:04
Speaker
try to quantify the extent and the severity of the motul skin of the patient.
00:08:12
Speaker
Perfect.
00:08:13
Speaker
And I believe it's a good reminder to our critical care colleagues that there is value in the physical exam.
00:08:19
Speaker
There is value in looking at our patients.
00:08:21
Speaker
And the modeling score is a perfect example of how you can try to be more objective with what you're observing.
The Prognostic Value of Physical Exams
00:08:27
Speaker
And studies have shown that it can tell you a little bit more about the direction your patient is headed.
00:08:32
Speaker
So something for people to maybe read a little bit about it.
00:08:35
Speaker
They're not using it at this time.
00:08:39
Speaker
Let's talk about... Yeah, there's no cost, only just lifting the sheets to see the kneecaps from the patient.
00:08:45
Speaker
So that's the only investment.
00:08:47
Speaker
It's a two-second test that can give you a lot of valuable information.
00:08:50
Speaker
Absolutely.
00:08:52
Speaker
Let's talk about capital refill time, which is obviously an important focus of the Andromeda shock industry.
00:08:59
Speaker
number one and number two clinical trials that we'll discuss in a second.
Measuring and Interpreting CRT
00:09:03
Speaker
But could you tell us a little bit about capillary refill time?
00:09:06
Speaker
And let's start with the proper technique to measure CRT.
00:09:11
Speaker
Perfect.
00:09:12
Speaker
So capillary refill time is a test that you can do at the bedside.
00:09:15
Speaker
How we standardized it in the Andromeda studies was to use a glass or plastic probe that generates a compression on the ventral side of the index finger.
00:09:27
Speaker
just to avoid the side, the hand that has an arc line, just to avoid, let's say, arterial flow disruptions due to the arterial line.
00:09:38
Speaker
But we compress for 10 seconds until the finger is blanched, and then it comes with a chronometer, the time it takes to visually recolorate to the color level that was beforehand.
00:09:50
Speaker
So this is the technique that we standardize for the Andromeda-Sherst 2.
00:09:54
Speaker
Other researchers have used other techniques.
00:09:56
Speaker
For example, Matias Jaquet-Lagres used a syringe to compress.
00:09:59
Speaker
So he standardized, let's say, the pressure with the syringe into the sternum.
00:10:08
Speaker
And there are others that have used more or less time.
00:10:11
Speaker
But the idea is to...
00:10:13
Speaker
whenever you're using it to try to do it objectively in the amount of pressure we use just the amount of pressure necessary to blanch the skin and to take the time with a chronometer and counting let's say mississippi's that could be for a way to do it what is considered a normal refill time in adults we we we have considered it as a
00:10:39
Speaker
Below three seconds.
00:10:40
Speaker
That's what we consider three or less seconds as a normal CRT.
00:10:45
Speaker
Over three seconds, we consider it abnormal and it prompts us or trigger us to do a clinical intervention.
00:10:51
Speaker
Okay, perfect.
00:10:52
Speaker
And in terms of interpreting the capillary refill time, Eduardo, it's basically a dichotomy, right?
00:10:57
Speaker
Abnormal or normal.
00:10:58
Speaker
It doesn't matter if it's, once it's above three seconds, it's abnormal.
00:11:05
Speaker
And if it's below three seconds, it's normal.
00:11:07
Speaker
Is that correct?
00:11:09
Speaker
In the studies, we did it like that.
00:11:11
Speaker
However, you know that a patient with 9 seconds is probably way sicker than a patient with 3.5.
00:11:20
Speaker
Also, the time can also give you information on the kinetics.
00:11:25
Speaker
Let's say a patient had 9 seconds, you give him 500 mL of fluid, and then it's 4.
00:11:31
Speaker
We're moving in the right direction.
00:11:32
Speaker
So I think the value itself is also...
00:11:37
Speaker
relevant because
CRT Measurement Considerations in Diverse Conditions
00:11:39
Speaker
it gives you a sense of trajectory.
00:11:42
Speaker
Yet for the study, we used this dichotomy to, let's say, patient was okay or not to continue or not pushing registration.
00:11:52
Speaker
Okay, perfect.
00:11:53
Speaker
And is there any caveats for skin color or other patient characteristics that a clinician should be aware of?
00:12:02
Speaker
Yeah, there are some patients that you have some issues measuring.
00:12:05
Speaker
For example, I don't know, Raynaud disease or severe vasculopathy.
00:12:09
Speaker
There's also another very interesting group that I think there's lack of research gone.
00:12:14
Speaker
That's cirrhotic patients because you know cirrhotic patients live in this vasodilated state.
00:12:19
Speaker
So we're running actually an observational study to try to find the best cutoff or if CRT or skin flow can actually measure or measure
00:12:32
Speaker
assessivity in this subset of patients.
00:12:35
Speaker
So I think there are other, let's say, limitations to its use.
00:12:41
Speaker
The skin color, it's kind of difficult sometimes in patients with darker skin.
00:12:47
Speaker
Other researchers have used other sites to measure, even there's some research in the tip of the nose or the ear lobel, but it's still in validation phase.
00:12:59
Speaker
In terms of the pathophysiological determinants of CRT, could you give us an overview of how sympathetic tone, endothelial and coagulation dysregulation, we talked about the microcirculation abnormalities and also at a microhemodynamic level.
00:13:14
Speaker
What are we seeing?
00:13:15
Speaker
What are we trying to interpret?
00:13:17
Speaker
Yeah, this is a great question.
00:13:19
Speaker
I love it because it's been one of our research areas the last five to ten years because CRT,
00:13:25
Speaker
Let's say we all know that the skin is, let's say there's a huge sympathetic tone innervation and in a stress or a fight or flight mode, the sympathetic tone will be activated and the flow of the skin will be diverted to, let's say, more noble organs.
00:13:43
Speaker
And from 300, 400 mL per minute, that's the part of the cardiac output that goes to the skin, it will be almost all diverted.
00:13:52
Speaker
into the other organs.
00:13:54
Speaker
And we did a lot of studies with the laser Doppler device to assess the relationship between CRT and skin blood flow.
00:14:02
Speaker
We did one here in Santiago and one in Paris, and we found a tight relationship with
Factors Influencing CRT and Related Studies
00:14:07
Speaker
skin blood flow and capillary refill time.
00:14:11
Speaker
The capillary refill time moved in an almost asymptotic way when, sorry, skin blood flow moved almost asymptotically when CRT increased.
00:14:21
Speaker
Yet, other of our collaborations with Professor Gustavo Spina in Cali, he has also assessed...
00:14:29
Speaker
let's say, the components of a cup refill time in a way that they're not only vascular flow, but also adrenergic stress or microvascular reactivity.
00:14:42
Speaker
Because when we compress and decompress the finger, we're also looking at, let's say, it's like a small vascular occlusion test, like the ones we did with this ischemia reperfusion with
00:14:53
Speaker
these studies for the NEERS device.
00:14:57
Speaker
So there must be also a component of, let's say, capacity of the microcirculation to adapt.
00:15:07
Speaker
And we might be testing it, especially when we do a 10-second compression.
00:15:12
Speaker
So this is like uncharted territory still for some of the research, but it's also really interesting to understand all the determinants of this territory, not only the macro circulatory determinant, but also the micro circulatory determinant.
00:15:47
Speaker
There is one study led by Professor Swan in China that assessed like almost 300 patients, and there was a nice correlation between sublingual microcirculatory etiogenity and flow measured by the mean flow index and an abnormal capillary refill plan.
00:16:03
Speaker
Yet it was not perfect.
00:16:04
Speaker
So probably there are two territories that are converging in some part, but not perfect.
00:16:11
Speaker
completely.
00:16:12
Speaker
Probably there's different vascular, probably the tongue is more central flow rather than the peripheral in the skin, etc.
00:16:24
Speaker
Also, there's another study that showed that the capillary refill time also correlates tightly.
00:16:29
Speaker
It was done by Andreas Grunauer in Austria with visceral organ flow.
00:16:35
Speaker
They measured the
00:16:36
Speaker
hepatic, splenic, and intestinal renal arteries flow, and these are patients with abnormal capillary refill time had ultrasonographic patterns of more resistance.
00:16:48
Speaker
So, how I interpret this corpus of evidence is probably that refill time is a window that's more accessible, cheaper, to other territories, and it's probably moving in the same directions, as you mentioned.
00:17:02
Speaker
Da Vinci said that simplicity is the ultimate sophistication.
00:17:06
Speaker
So instead of using all these fancy devices, maybe all we should use is the tip of a fingertip, right?
00:17:13
Speaker
Yeah, that's the attractiveness.
00:17:15
Speaker
I think that's one of the great added values.
00:17:17
Speaker
That's just costless and you don't have to do this.
00:17:21
Speaker
cumbersome techniques to assess an organ proficient.
00:17:24
Speaker
Excellent.
00:17:25
Speaker
Let's dive into the evidence behind the application of CRT at the bedside.
00:17:31
Speaker
And obviously there's a body of literature that has looked at CRT.
00:17:35
Speaker
You measured Professor Max Weil, who I mean was pioneered I think in the 70s looking at toe temperature and other parameters in the skin for sure.
00:17:46
Speaker
But in terms of specifically what I wanted to focus on was on Andromeda Shock and Andromeda Shock 2 recently published in JAMA.
00:17:54
Speaker
So maybe we can start with Andromeda Shock and you could give us a little bit, an overview of the study, the hypothesis and what you found and what it means.
Comparing CRT-Guided Resuscitation to Lactate Normalization
00:18:06
Speaker
Perfect.
00:18:06
Speaker
So I'll start with, let's say, something that's similar to the Motley core.
00:18:10
Speaker
There's a meta-analysis by Matthieu Jaquette-Lagrรจce that shows that an abnormal cap ratio time is associated with worse outcomes.
00:18:16
Speaker
So it's also a prognostic...
00:18:19
Speaker
the value technique with a NUTs ratio of 4 or 5, but when the technique is done properly, it increases over 10.
00:18:28
Speaker
So we have a very nice clinical tool that can help us identify patients at risk of death.
00:18:33
Speaker
But also, one of the beauties of capillary refill time is that it has a fast kinetic response,
00:18:40
Speaker
in which patients that are adequately resuscitated or with macromodynamic interventions, patients respond in less than 15 or 20 minutes by improving cap refill time.
00:18:49
Speaker
There's a study by Lisa Raya that showed that after a fluid bolus, the patients that responded responded in 15 minutes.
00:18:55
Speaker
They measured every two minutes and they noticed that CRT was super fast compared to other, let's say, perfusion parameters.
00:19:02
Speaker
And we had a paper in 2014
00:19:04
Speaker
that we tracked 100 survivors of septic shock, and every four hours we did lactate, microcirculation, sublingual microcirculation, cap refill time, and other derived, let's say, perfusion variables.
00:19:20
Speaker
And we saw that patients that survived normalized cap refill time at two hours, 70% of them, while 50% of them had an abnormal lactate,
00:19:29
Speaker
let's say, after 24 hours.
00:19:31
Speaker
So lactate presented like a B-facic kinetic, and it had a rapid normalization, but then it was slower to normalize.
00:19:42
Speaker
And that was the basis for the Andromeda shock one.
00:19:44
Speaker
They basically compared a resuscitation strategy following cap refill time,
00:19:50
Speaker
versus a recitation strategy following lactate decrease or normalization.
00:19:56
Speaker
And this study was done in five countries in Latin America.
00:19:59
Speaker
It involved 424 patients and it was published in JAMA in 2019.
00:20:05
Speaker
And both recitation strategies were the same.
00:20:07
Speaker
Let's say fluid responsiveness tested first, if the patient was not a fluid responder or had a or
00:20:16
Speaker
or became non-fluoresponder but still had an abnormal value of the perfusion target, came a MAP challenge and then a 9-0 probe challenge.
00:20:24
Speaker
So it was the same strategy but with a different target.
00:20:27
Speaker
And the study showed that patients that were randomized to cap refill time had a
00:20:34
Speaker
It had an 8% absolute decrease in mortality, that even though it had a p-value of 0.06, a Bayesian reanalysis after published by Fernando Sampieri showed that it had a very, let's say, high chance of being positive for clinical practice.
00:20:52
Speaker
But also, patients received less fluid and had less organ dysfunction.
00:20:56
Speaker
So this study came to challenge, let's say, the standard of care that was pursuing lactate normalization or decrease by using bed-safe techniques such as capillary refill time.
00:21:08
Speaker
That was the Andromeda-SHOQ1 trial, and it made a lot of, let's say, positive noise in the sense that capillary refill time that was, let's say, sometimes looked...
00:21:22
Speaker
over the shoulder because it's a technique that's at the bedside.
00:21:28
Speaker
It appeared in the guidelines.
00:21:30
Speaker
The 2021 Surviving Sepsis Campaign brought it up and it boomed a lot of research and clinical translation of this technique.
00:21:42
Speaker
That was Andromeda Strap I.
00:21:44
Speaker
Perfect.
00:21:45
Speaker
And just to put some perspective, right?
00:21:49
Speaker
Capitaly refill time is something that has been investigated and there were small studies looking at its prognostic factor for decades.
00:22:00
Speaker
And Andromeda...
00:22:01
Speaker
Andromeda Shock 1 brought it back to the forefront, like you said, and really started a new wave of interest in applying a very simple bedside intervention to guide therapy that is a lot more accessible to clinicians in terms of time, in terms of cost, in terms of availability.
00:22:21
Speaker
And that led, I presume, to Andromeda Shock 2, which we'll talk about now.
00:22:26
Speaker
Yeah, yeah, and what's nice is that also the philosophy behind the study was to put the tissue perfusion as a hierarchical target, you know?
00:22:34
Speaker
It was not to normalize macromodynamics, a cardiac index, a minor arterial pressure, or no, it was we manipulated the macromodynamics in order to restore tissue perfusion.
00:22:44
Speaker
I think that was very nice, and following probably the reverse study, then the lactate trial published in the Blue Journal, so it's a change of the pendulum of focusing solely from the macro,
00:22:55
Speaker
to following to the tissue proficient.
00:22:57
Speaker
That's our end goal.
00:23:02
Speaker
Perfect.
00:23:03
Speaker
So let's, let's go ahead.
00:23:04
Speaker
Perfect.
Andromeda Shock 2 Trial and CRT
00:23:11
Speaker
So after we finished 2019, we all suffered the pandemics, so we had this two-year gap.
00:23:20
Speaker
And in 2021, we started thinking of how can we push this further?
00:23:24
Speaker
Can we test?
00:23:27
Speaker
How can we still keep improving hemodynamic resuscitation of septic shock patients?
00:23:32
Speaker
And after months of discussion, we came with the idea
00:23:36
Speaker
We have one side of the face of the coin, that's the capillary refill time.
00:23:40
Speaker
That's simple, it's, let's say, easy to do, and we've already brought up this corpus of evidence.
00:23:47
Speaker
But what about the macromodynamics?
00:23:49
Speaker
Can we try to do something as simple as capillary refill time, but in order to personalize resuscitation?
00:23:57
Speaker
At that time, we had some nice papers by Guillaume Guiri and Anton Vilevarรณn that showed that there was...
00:24:03
Speaker
hemodynamic clusters, and there were quite heterogenic patterns of hemodynamic clusters or cardiovascular clusters in patients.
00:24:14
Speaker
So we started thinking, iterating ideas, and we came, okay, we need to perform an algorithm that's able to
00:24:24
Speaker
individualized care, not go like one step at a time, but let's do like more branching in the algorithm, but using simple tools.
00:24:33
Speaker
And that's where we came with, let's use pulse pressure and diastolic arterial pressure to identify patients that have a low stroke volume, either by low cardiac,
00:24:43
Speaker
right or left ventricular failure or hypovolemia, and the astolic blood pressure as a surrogate for, let's say, vascular tone.
00:24:51
Speaker
So that's how we started building this, always aiming at caperitial time, formalization.
00:24:57
Speaker
And we also said...
00:24:58
Speaker
we must include a cardiac evaluation with ECHO, but reserved for those that do not resolve the hyperperfusion or do not normalize capricutin with the simple interventions.
00:25:10
Speaker
And that's where the main changes from andromedal stroke 1 to 2, which we use pulse pressure and the esthetic blood pressure to, let's say, try to divide patients that have predominant vasoclycia or pulmonary
00:25:24
Speaker
low stroke volume, and we integrated a cardiac echo at the start of Tier 2.
00:25:29
Speaker
And the other pillars are just the same, that's fluid responsiveness before every fluid challenge, and the tests, let's say the mean arterial pressure test and the inodulator test, that are reversible tests that allow us to type-take hemodynamic interventions to normalize cap refute.
00:25:48
Speaker
So this trial, we started recruiting patients in 2022, and it was super nice because we grew beyond Latin America.
00:25:56
Speaker
We had centers in North America, Western Europe, and Asia, and it's finalized with a drug community of researchers and clinicians,
00:26:08
Speaker
that participated in the study.
00:26:10
Speaker
And we recruited 1,500 patients in the span of three years.
00:26:15
Speaker
And we did the study with no financing at all.
00:26:17
Speaker
It was super nice.
00:26:19
Speaker
Everyone that wanted to participate had to find their own financing if they're required.
00:26:26
Speaker
But I think the sense of community and the sense of building this together was the main driver that allowed us to complete
00:26:34
Speaker
the recruitment of the study in a record time of three years for 1,500 patients.
00:26:41
Speaker
And this was the study design and the, let's say, the people involved.
00:26:46
Speaker
And we had such a collaboration from whole research groups, not only here in Latin America, but in Spain, there was this anesthesia society that
00:26:56
Speaker
went in a block together, and they were super inspirational.
00:27:03
Speaker
The French team also won a grant, and they started computing.
00:27:08
Speaker
And we had some... There's a very nice human story behind the Andromeda structure.
00:27:15
Speaker
But coming back to the study, sorry I diverged.
00:27:18
Speaker
Now we have this protocol, we developed this algorithm, and we wanted to compare to what we were going to compare to.
00:27:25
Speaker
And that's when we decided, okay, we cannot give another, let's say, protocol, like it was the Andromeda 1 that we compared to lactate, so we chose to compare to usual care.
00:27:36
Speaker
And we were discussing the outcomes, our statistical genius, that's Alexandre Biasica-Valcanti from Brazil, said, I guess I want to propose to use a composite primary outcome, but not in a composite like in an old-fashioned way where every component of the composite outcome weighs the same.
00:27:55
Speaker
There's a rather new way to process.
00:27:58
Speaker
To use these composite outcomes, it's called the win ratio, which we use a hierarchy on the outcomes and the highest of the hierarchy have more way into the final metric.
00:28:09
Speaker
So that's when we say, okay, let's do it this way.
00:28:12
Speaker
And we involved three outcomes.
00:28:14
Speaker
There was mortality, length of organ support, and hospital length of step.
00:28:22
Speaker
So we use this hierarchical outcome to address our research question.
00:28:29
Speaker
And as I told you, it was 1,500 patients and
00:28:34
Speaker
The primary outcome was positive.
00:28:36
Speaker
We had a 1.16 win ratio that was mainly driven by duration of organ support.
00:28:43
Speaker
That was our second tier outcome.
00:28:46
Speaker
So we were super happy on this, not only on the results, but in the process itself.
00:28:51
Speaker
There was human growth.
00:28:54
Speaker
We made bonds with people around the world and was a researcher-led study.
00:29:01
Speaker
And I think it's worth taking a second to really appreciate the unique nature of Andromeda Shock 2, which is, like you mentioned, was 100% investigator-driven and did not have any external funding and was really a...
00:29:19
Speaker
a work of passion and true curiosity and finding better ways of treating our patients.
00:29:25
Speaker
So kudos to you and the whole team.
00:29:28
Speaker
Really a phenomenal testament to what we can achieve when we really have a will.
00:29:34
Speaker
So congratulations.
00:29:36
Speaker
And what I wanted to ask you, Eduardo, was could you talk a little bit more about the primary outcome?
00:29:42
Speaker
Because like you mentioned, composite outcomes over the last couple of years have become more common in critical care, clinical trials.
00:29:50
Speaker
But the idea of using a hierarchical composite outcome is a little bit more novel.
00:29:54
Speaker
It's not as common.
00:29:56
Speaker
And if I recall from reading the paper, the primary outcome was basically an order of importance mortality,
00:30:03
Speaker
duration of vital support, which included vasoactive drugs, mechanical ventilation, and kidney replacement therapy, and then finally, the length of hospital stay, and all that measure at 28 days.
00:30:14
Speaker
Is that correct?
00:30:15
Speaker
That's correct.
00:30:16
Speaker
So the idea of this outcome is just to give a higher value to those that are on the top of the hierarchy.
00:30:22
Speaker
So in the practical way, how do you do it?
00:30:25
Speaker
You compare each patient...
00:30:28
Speaker
from the intervention group to each patient to the control group.
00:30:31
Speaker
So patient one, you compare to patient one of the control group, patient one, you compare to patient two, then patient three, and that makes you a number of comparisons.
00:30:41
Speaker
That's basically the number of patients in one group multiplied by the number of patients in the other group.
00:30:46
Speaker
And in each comparison, you compare either a win,
00:30:51
Speaker
a tie or a lose.
00:30:53
Speaker
So, for example, if the patient on the intervention lived and in the control died, it's a win to the intervention.
00:31:01
Speaker
If the patient of the control group lives and the patient in the intervention group dies, it's a win to the control.
00:31:08
Speaker
And if both patients survive, it's a tie, and then you go to the next hierarchy.
00:31:13
Speaker
You compare the duration of organ support only to those that survived in the first one.
00:31:19
Speaker
And then you do the same.
00:31:21
Speaker
So if in the Tier 2 or in the outcome number 2, there's 20 days and then it has 19 days of duration of organ support, it's a win for control.
00:31:32
Speaker
But if both have 20 days, you tie, and then you compare all in those that tie,
00:31:36
Speaker
the third outcome.
00:31:37
Speaker
So that way you give a higher value to the most relevant outcome, first mortality, then duration of organ, and then a hospital length of stay.
00:31:46
Speaker
Okay, that's perfect.
00:31:47
Speaker
Now I understand a bit better.
00:31:49
Speaker
And that means that at the end, I mean, you basically had 700 plus times 700 plus comparisons, so a large number of comparisons.
00:31:59
Speaker
Yeah, it was one, like 200, let me open the paper to give you the exact number, because we did it stratified by Apache, so it changed a bit, but the idea is that it's thousands, hundreds of thousands of comparisons to find this.
00:32:18
Speaker
this difference, you know, to make this the indicator.
00:32:22
Speaker
And I want to dive a little bit more into the protocol itself in one second.
00:32:29
Speaker
But in terms of the study itself, so 1,500 patients with septic shock, all adults, were there any major exclusion criteria that are relevant to
00:32:40
Speaker
You mentioned earlier questions about cirrhosis in terms of CRT, so I presume that was included.
00:32:47
Speaker
But what are some of the patients that were excluded from the study?
00:32:50
Speaker
Yeah, so yeah, it's a really bad point.
00:32:52
Speaker
I didn't highlight this.
00:32:54
Speaker
There's some exclusion criteria, for example, patients that had more than four hours since diagnosis.
00:33:00
Speaker
So we had a small time frame because we wanted to focus on early septic shock.
00:33:04
Speaker
Also, if patients were going to go to surgery and we could not continue the six-hour, let's say,
00:33:10
Speaker
the time span of the study, or patients that had, let's say, severe ARDS, DNR, or pregnancy, that these are like usual exclusive criteria for septic shock studies.
00:33:29
Speaker
I think those are the major ones, let's say.
00:33:32
Speaker
Perfect.
00:33:33
Speaker
And in terms of the actual protocol or the intervention, one important aspect I want to emphasize is that as the title says, the idea here was to personalize hemodynamic treatment based on CRT as part of a protocol.
00:33:51
Speaker
So this was not like one protocol that is applied to everybody the same way, but you tried to identify different phenotypes, let's call it, or different categories of patients based on the response to shock.
00:34:03
Speaker
So you did mention earlier that in the personalized hemodynamic recitation protocol that was targeting CRT, there was a Tier 1 and Tier 2.
00:34:12
Speaker
Could you explain that in more detail?
00:34:14
Speaker
Yes, of course.
00:34:16
Speaker
So our idea was to handle atherogenity,
00:34:21
Speaker
within the protocol itself, because patients are quite heterogeneic.
00:34:24
Speaker
So we started with a two-tiered approach.
00:34:27
Speaker
So tier one is the simpler interventions, and the first assessment was cap refill time.
00:34:32
Speaker
If cap refill time was normal, we did not do any further intervention, just observe hourly.
00:34:39
Speaker
Of course, during the six-hour patient deteriorated, we intervened.
00:34:42
Speaker
But let's say a patient with a normal cap refill time had...
00:34:48
Speaker
Then if the patient had an abnormal cap refill time, we assess pulse pressure as our first, let's say, branching tool.
00:34:56
Speaker
If the patient had a low pulse pressure, we check fluid responsiveness with the technique that the clinician had at the moment and according to the patient characteristics.
00:35:06
Speaker
And if the patient was food responsive, we gave food challenges up to 1,000 mLs.
00:35:12
Speaker
If the patient had a normal pulse pressure and a low diastolic blood pressure, less than 50, we say, wait, here's an issue here.
00:35:20
Speaker
It's probably done by predominant vasoplegia.
00:35:23
Speaker
So we titrated norepinephrine to increase diastolic blood pressure over 50.
00:35:29
Speaker
As you know, the main determinants of diastolic blood pressure is vascular tone and the heart rate.
00:35:35
Speaker
So if neither of these interventions, either fluids or the diastolic test, let's say, increased or normalized cab refill time, we went to Tier 2.
00:35:44
Speaker
It was a bit more labor-intensive, and it started with echo to check for right ventricular or left ventricular failure.
00:35:52
Speaker
If we found those, we treated them according to the local clinician guidance.
00:35:57
Speaker
If there was no cardiac echo, we checked again for fluid responsiveness to assess if further fluids could make the trick and improve capillary ratio time.
00:36:07
Speaker
if even though there's no fluids where the or patient was not fluid responder or whatnot, we did the same as sending Andromeda 1.
00:36:14
Speaker
We did a test to in those patients that were previously hypertensive to transiently increase mean arterial pressure to 80-85 and checking one hour.
00:36:24
Speaker
If the CRT normalized,
00:36:28
Speaker
we kept these high targets.
00:36:30
Speaker
If the CRT was not normal, we went back to 65, there was a previous baseline level, and did a low dose of vitamin test with 5 micrograms per key.
00:36:42
Speaker
For one hour as well, to check if in a reversible fashion we could improve cap refill time.
00:36:49
Speaker
So this was like the overview of the protocol, but our idea behind it was to, let's say, stratify interventions with Tier 1 and Tier 2, and to try to address heterogeneity according to the determinant phenotype, as you mentioned, or let's say, cardiovascular cluster of patterns.
00:37:07
Speaker
Excellent.
00:37:08
Speaker
But it started with CRT as the first determination.
00:37:12
Speaker
And even if you had no access, and we'll talk about the practical implications to echo, Tier 1 probably involved a large proportion of patients, right?
00:37:24
Speaker
So you can start with Tier 1.
00:37:26
Speaker
Go ahead.
00:37:27
Speaker
Sorry, sorry.
00:37:28
Speaker
So actually, in the supplement, we added one figure with the individual predictors of patients, and 65% of patients normalize cap refill time with Tier 1.
00:37:39
Speaker
So only one in three had to go to Tier 2.
00:37:42
Speaker
And of course, echo could be a limiting factor.
00:37:45
Speaker
In fact, there's a study done in the UK where less than 7% of patients admitted to the ICU receive an echo during the first hour.
00:37:55
Speaker
So when we designed this algorithm, we were conscious about this, especially because most of the patients, or many patients, were randomized in research constraint settings.
00:38:07
Speaker
So we have to put echo as a second level, let's say,
00:38:12
Speaker
strategy because or else it won't be practical.
00:38:17
Speaker
So in summary, both Andromeda shock one and shock two were positive studies.
00:38:22
Speaker
It seems that in Andromeda shock one, the comparison to using what at that time was recommended, which was lactose clearance was equivalent.
00:38:30
Speaker
And when you did post hoc analysis with Bayesian approaches, there was an increased probability of improved mortality and a clear signal to a lower utilization of fluids and basal active drugs.
00:38:42
Speaker
Correct.
00:38:45
Speaker
And in shock two, what you demonstrated was that with a composite hierarchical primary outcome, there was a positive
Integrating CRT into Clinical Practice
00:38:54
Speaker
signal or positive finding that was statistically significant with using CRT to personalize your hemodynamic result in terms of that outcome.
00:39:04
Speaker
And that was driven mostly to the use of life support or vasoactive renal support and mechanical ventilation treatments.
00:39:13
Speaker
Correct.
00:39:15
Speaker
Yeah, correct.
00:39:16
Speaker
So in terms of... I will say that, yeah.
00:39:20
Speaker
In terms of moving on to practical considerations, so we have two... We have a body of literature suggesting the prognostic value.
00:39:29
Speaker
We now have two wonderful studies showing its applicability at the bedside.
00:39:35
Speaker
But we always have to translate from clinical trials, which are very motivated, very controlled settings, to...
00:39:43
Speaker
using it in the wild, right?
00:39:45
Speaker
And applying it at the bedside.
00:39:47
Speaker
So my question, my question for you, Eduardo, is practical considerations.
00:39:55
Speaker
What are some of the challenges of incorporating CRT into your resuscitation as a clinician?
00:40:01
Speaker
I think, let's say, one of the barriers I found is to do it in a standardized fashion.
00:40:08
Speaker
And maybe for the clinical practice, you can do it like
00:40:12
Speaker
without a glass probe or maybe you can compress with your finger, you know, that's beyond the clinical research scenario.
00:40:21
Speaker
It's probably an easier way to bring the CRT to the bedside.
00:40:26
Speaker
Also regarding, let's say, there have been some criticism to this algorithm, saying that it's kind of labor-intensive and branches out.
00:40:36
Speaker
And for me, and I'm speaking personally now, I think
00:40:39
Speaker
Probably maybe in five to ten years, this is not the last algorithm.
00:40:43
Speaker
But what I think what we showed here, super humbly, I think, is that...
00:40:49
Speaker
Personalizing therapy matters, you know, giving fluids to those with high probability of fluid responsiveness.
00:40:56
Speaker
If the patient has a vasoplegic tone, let's try to address that first.
00:41:00
Speaker
Let's check for cardiovascular dysfunction.
00:41:03
Speaker
And maybe this algorithm will not be the final algorithm, you know, and maybe to adapt it to your clinical scenario, you have to do, or if you are an echocardiography lover, you will do echocardiography.
00:41:18
Speaker
But the value I think is,
00:41:20
Speaker
to bring together the hemodynamic resuscitation in a personalized fashion with a tissue perfusion.
00:41:27
Speaker
As well, we're not always looking only at capillary field time.
00:41:30
Speaker
We have to create context, and we are checking the lactate, the simple venous saturation, CO2 gap.
00:41:35
Speaker
So in the clinical, every day, we're looking at a broader movie, let's say.
00:41:42
Speaker
But the important thing is that we can mix this work together and try to give our patients what they require.
00:41:47
Speaker
Yeah.
00:41:49
Speaker
I also believe after reading this and thinking about the results that there is no question in my mind that any intervention that brings us to the bedside and forces us to think about that individual patient is probably positive.
00:42:04
Speaker
And really that being the route of personalization, right?
00:42:08
Speaker
That to think about in this particular patient, what is the right answer?
00:42:12
Speaker
And we might be wrong sometimes, but on average, if we spend more time thinking about the individual patient, we're more likely to have a better process and that would lead to better outcomes.
00:42:21
Speaker
So that is also very valuable to really apply this at the bedside and really try to find the best answer for that individual patient.
00:42:33
Speaker
And the value to, as you mentioned, to do something, intervene, and then reassess and be there.
00:42:38
Speaker
You know, just like be there with the patient and close this loop.
00:42:41
Speaker
Like, okay, I'm giving an increasing MAP, and I'm not doing it like flipping a coin and say high MAP versus low MAP, because that could work in an RCP.
00:42:50
Speaker
But in the daily clinical practice, you can increase MAP and then check the
00:42:55
Speaker
I didn't work out, so I'll avoid exposing the patient to more of a tract.
00:42:59
Speaker
So I think this closing the loops and testing, I think at the end of the day, as you say, brings us closer and allows us to individualize.
00:43:11
Speaker
Absolutely.
00:43:12
Speaker
And after all the research that has been done over the last 20 years on hemodynamic monitoring, what has been clear from my perspective is that dynamic is better than static.
00:43:24
Speaker
And this is a dynamic application of a hemodynamic monitoring tool.
00:43:30
Speaker
And like you said, it really helps us personalize better our interventions.
00:43:35
Speaker
You mentioned earlier, Eduardo, the sepsis guidelines and how after Andromeda 1, it got included into the recommendations for CRT.
00:43:45
Speaker
What do the guidelines say right now?
00:43:47
Speaker
And obviously, that last iteration of the guideline was published prior to Andromeda Shock 2, but I'm just curious to see where the guidelines stand today.
00:43:54
Speaker
Yeah.
00:43:56
Speaker
Today they say that, I'm paraphrasing now, but they say to use lactate and its clearance as guiding, let's say, resuscitation, and also that capillary time can be used as an agent measure to guide resuscitation.
00:44:15
Speaker
How would you... Go ahead.
00:44:18
Speaker
Yeah, and there was a ESICM, let's say,
00:44:23
Speaker
Telphi panel, published this year on how to conduct with subject-socure resuscitation on resource constraint settings, and they recommended a capillary full-time to guide resuscitation as well.
00:44:37
Speaker
And since you mentioned that, I know ESAM also had a panel recently on the later phases of resuscitation, which is de-resuscitation or what we do when we've stabilized the patient and now have perhaps fluid overload.
00:44:52
Speaker
Is there value in using CRT in that de-resuscitation phase or evacuation phase?
00:45:00
Speaker
I love this question because it's also one of the uncharted territories and it's also been part of the ongoing research by many groups.
00:45:09
Speaker
There's a paper by the group of Fabio Silvio Taconi that assessed the laser doppler when patients were connected to ultrafiltration
00:45:16
Speaker
and the laser Doppler, let's say skin blood flow, decreased earlier than the, let's say, ultrafiltration intolerance with macro-hemodynamic instability.
00:45:28
Speaker
So it could also serve as a guide to the unresuscitate patients and integrate tissue perfusion as well.
00:45:37
Speaker
There's also some data
00:45:41
Speaker
but it's also very, very, let's say, from the research arena, that the microcirculation can also be affected by venous congestion.
00:45:49
Speaker
So if a patient is fluid overloaded with a high CVP, with, let's say, a high VEXO score, it would be interesting to address as well and assess if this impacts, let's say, or if there is a following of the capillary result time abnormality.
00:46:05
Speaker
But this is also in the research.
00:46:07
Speaker
still in the research context and I could not provide certain evidence.
00:46:11
Speaker
But I think as we're doing it and doing the resuscitation in which we're taking only, not only, macromodynamics to guide resuscitation but also tissue perfusion, I think that in the next years we will see a bunch of literature addressing tissue perfusion as well in the deregistative phase to avoid second and third hits.
00:46:33
Speaker
And it makes sense, right?
00:46:34
Speaker
If it's useful on the way up, it should be useful on the way down.
00:46:36
Speaker
Yeah.
00:46:37
Speaker
Yeah, absolutely.
00:46:39
Speaker
We have to create the literature as well.
00:46:41
Speaker
Perfect.
00:46:43
Speaker
How would you recommend CRT be utilized today in clinical practice?
00:46:49
Speaker
I think one of the beauties, let's say, of caprifield time is that it's simple, it's costless, and it can be done almost anywhere.
00:47:00
Speaker
So I think that...
00:47:05
Speaker
Cap-refill time can be used in the emergency room.
00:47:08
Speaker
There's some nice papers using as a triage, admission criteria, also to assess patients.
00:47:16
Speaker
We did a study in Mexico in critically ill-obstetric patients, and we saw that even though most of them have preeclampsia, patients with abnormal cap-refill time were usually admitted to the ICU.
Future CRT Applications in Critical Care
00:47:30
Speaker
There's a study by Mergy et al.
00:47:32
Speaker
that used capillary refill time in cardiogenic shock.
00:47:35
Speaker
So I think there's a broader growth of CRT to other critically ill diseases beyond septic shock.
00:47:45
Speaker
And of course, pediatricians and pediatric intensivists have used capillary refill time for many years as a daily clinical practice.
00:47:53
Speaker
So I think it's a prognostic tool.
00:47:57
Speaker
can help us to guide resuscitation during a septic shock.
00:48:04
Speaker
And also, I hope that we can see some value on, as you mentioned, on the de-resuscitation phase.
00:48:12
Speaker
Any common pitfalls to avoid and pros for practical success you want to share as we close?
00:48:18
Speaker
Yeah.
00:48:19
Speaker
Sometimes I, I, uh, there are some literature to support these to do more than one measurement than have an average just to increase, uh, to avoid, uh, let's say, um, heterogeneity in the measurements.
00:48:31
Speaker
Uh, if you can use a chronometer, use a chronometer to, to, to, to make it more objective in the measurement.
00:48:39
Speaker
And, um, I think.
00:48:42
Speaker
that as with any complex disease and any complex scenario, don't take decisions only based on one parameter, but look at the global picture and assess in the clinical practice all other signals that are talking about the cardiovascular deficiency and tissue perfusion.
00:48:57
Speaker
Let's say if the patient is awake, he's peeing, and he's, let's say, with a little bit of norepinephrine, you say, hopefully this patient that is warm, awake, and peeing is probably okay.
00:49:10
Speaker
And with the same vasoactive drug dose, if the patient has a motiline score, lactate is rising, and the patient is anemic, probably you have an issue.
00:49:19
Speaker
So not focusing only one thing, but let's say build a broader picture.
00:49:26
Speaker
What are some developments that you are anticipating and are most excited about in the future?
00:49:33
Speaker
I hope that, well, you know the story of the reverse trial that later was tried again in three other big trials.
00:49:43
Speaker
So I hope there's a new interest on doing something similar.
00:49:48
Speaker
that testing an hypothesis with a broader spectrum or a clinical, I don't know, maybe in the US, they will start an Andromeda US study, something like that.
00:49:58
Speaker
And I hope to see it validated by different groups or tested at least the hypothesis by different groups.
00:50:06
Speaker
I think that there will be a renowned interest by industries to
00:50:10
Speaker
make, I don't know, semi-automatic or automatic monitors addressing capital and refill time.
00:50:15
Speaker
And for me, what are my research agenda, at least personally, is I'm very interested in venous congestion and see how this can affect organ and tissue perfusion.
00:50:25
Speaker
And
00:50:27
Speaker
how can we guide this, let's say, resource more gently with this, let's say, trying to improve tissue perfusion without inducing venous congestive.
00:50:40
Speaker
I think this would be nice.
00:50:42
Speaker
And also one of my interests is this great concept of refractory shock, what it is.
00:50:49
Speaker
Each one of us has a definition of its own, so I think it would be nice to come to Common Grounds.
00:50:55
Speaker
So we can also...
00:50:56
Speaker
start doing research on this area.
00:51:00
Speaker
That is the beauty of having great questions.
00:51:02
Speaker
It just leads to more great questions, right?
00:51:05
Speaker
Yeah.
00:51:06
Speaker
Yeah, yeah.
00:51:06
Speaker
Sometimes it's like an Everest, but I think with a nice team and good friends, you can always try to bring them to the most.
00:51:14
Speaker
Absolutely.
00:51:15
Speaker
Eduardo, we'd like to close the podcast with a couple of questions that are unrelated to the clinical topic.
00:51:22
Speaker
Would that be okay?
00:51:23
Speaker
Yes, of course.
00:51:24
Speaker
I'd love to.
00:51:25
Speaker
The first question relates to books.
00:51:27
Speaker
Is there a book or books that have influenced you significantly or a book that you have gifted often to other people?
00:51:34
Speaker
Yes, yes.
00:51:35
Speaker
For me, it's like a story book that I read and now I'm reading to my children, The Little Prince by Antoine de Saint-Exupรฉry.
00:51:43
Speaker
It's been a... It's come with me at different stages of my life and every time you read it, it brings new...
00:51:52
Speaker
let's say, ideas or messages.
00:51:55
Speaker
And the book that I'm reading now is called The Autumn Ghost by Hannah Wunsch.
00:52:01
Speaker
I don't know if you had the opportunity to read it.
00:52:03
Speaker
It's about the polio pandemics.
00:52:07
Speaker
I'm really enjoying it.
00:52:08
Speaker
I'm reading it now, and I'm really enjoying it.
00:52:12
Speaker
And for our listeners who have not read The Little Prince, it is a quick read.
00:52:17
Speaker
But like you said, Eduardo, every time you read it, you learn new things and you think about different aspects of life.
00:52:24
Speaker
But truly an enduring and wonderful book that is highly recommended.
00:52:30
Speaker
The Autumn Ghost is...
00:52:32
Speaker
a book about the polio epidemic, which really is the birth of critical care, right?
00:52:38
Speaker
So it's really where our specialty started.
00:52:40
Speaker
So highly recommended by one of our wonderful colleagues.
00:52:44
Speaker
And I will link both of them in the show notes.
00:52:46
Speaker
So thanks for sharing those.
00:52:48
Speaker
The second question relates to changing your mind.
00:52:54
Speaker
And could you share with us something you changed your mind about recently?
00:52:58
Speaker
Yeah.
00:52:59
Speaker
Yeah, yeah, I think I would like to, well, we could talk about many things over here, but for me, what I'd like to share is the journey of doing research.
Reflecting on the Research Journey
00:53:15
Speaker
So for me, at the beginning, you wanted to get to the answers, and you hoped that your hypothesis was correct, and I think
00:53:24
Speaker
after finishing the Andromeda SHOEK-2 trial, it's the journey itself that's the most beautiful, you know?
00:53:31
Speaker
It's getting to know such nice and beautiful people along the way, how to do it properly, and independent of the result, I think the journey itself has been so enriching, and it's been
00:53:45
Speaker
Such a, let's say, a wonderful ride.
00:53:48
Speaker
It has its drawbacks, its sour moments as well.
00:53:52
Speaker
But it's been so nice that I think for me the lesson or what I've changed my mind about is not just focusing on the goal.
00:54:01
Speaker
but on the journey and that applies to everything in life.
00:54:04
Speaker
I think it's a great analogy for life and which really the lesson that over and over has been learned, I think in different traditions has been that the real value lies in the journey.
00:54:17
Speaker
And we definitely will have to talk more about that and would love to have you back to talk about new developments soon.
00:54:25
Speaker
But to close, I would like to ask you one final question.
00:54:29
Speaker
What would you want every listener to know?
00:54:34
Speaker
Oh, this is a tough one, but I think that it's okay to be wrong sometimes.
00:54:43
Speaker
It's in an argument with a family member.
00:54:50
Speaker
It's in a clinical scenario that you have a mindset and you're answering with your own biases.
00:54:57
Speaker
It could be with, let's say, I don't know.
00:54:59
Speaker
Discussing with a friend, but it's okay to be wrong.
00:55:05
Speaker
It's difficult sometimes not to be super, let's say, exigente.
00:55:12
Speaker
How do you say it in English?
00:55:13
Speaker
Let's say... Demanding.
00:55:17
Speaker
Demanding with yourself.
00:55:18
Speaker
So it's okay sometimes to cut a bit of slack and be, let's say...
00:55:25
Speaker
We're humans, you know?
00:55:27
Speaker
Failure is what makes us humans.
00:55:32
Speaker
I agree.
00:55:32
Speaker
So embracing failure and learning from it, I think.
00:55:35
Speaker
And I think one way to summarize, and it's a beautiful thought, is don't aim to be right, aim to learn.
00:55:45
Speaker
Yeah.
00:55:46
Speaker
And in order to learn, we have to fail.
00:55:49
Speaker
Right.
00:55:50
Speaker
Yeah.
00:55:50
Speaker
So that should be the path forward.
00:55:53
Speaker
Eduardo, thank you so much for sharing your time and your expertise with us.
00:55:58
Speaker
We definitely would love to have you back in the future to talk about other fascinating topics.
00:56:04
Speaker
And again, congratulations on Andromeda Shock 2.
00:56:08
Speaker
And I look forward to talking with you more.
00:56:11
Speaker
Thank you.
00:56:12
Speaker
Thank you for the opportunity of being here.
00:56:13
Speaker
Again, this is a collective, let's say, milestone with more than 800 researchers involved in this study.
00:56:22
Speaker
And it's such a wonderful opportunity to be sharing it with you and all your team.
00:56:26
Speaker
So thank you very much.
00:56:29
Speaker
Thank you for listening to Critical Matters, a sound podcast.
00:56:33
Speaker
Make sure to subscribe to Critical Matters on Apple or Google Podcasts and share with your network.
00:56:39
Speaker
Sound's transforming the way critical care is provided in hospitals across the country.
00:56:43
Speaker
To learn more, visit www.soundphysicians.com.